Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC

In our exclusive interview, Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.